Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Overview

Información sobre este estudio

The purpose of this study is to determine if glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment.  

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Informed consent obtained before any trial-related activity

- Completed the full treatment period of the extension trial EASE SBS 2 (ZP1848-17127)

Exclusion Criteria:

- Any condition, disease, or circumstance that in the Investigator's opinion would put
the patient at any undue risk, prevent completion of the trial, or confound the
planned assessments of the trial

- Not having a colonoscopy performed at End of Trial in EASE SBS 2 (for patients with
remnant colon). Note. The results of the colonoscopy must not give rise to any safety
concerns. A colonoscopy performed within 6 months prior to End of Trial and not giving
rise to any safety concerns is accepted. For patients with a remnant colon, which is
not connected to the passage of foods and is thereby dormant, a computerized
tomography (CT) scan or magnetic resonance imaging (MRI) will suffice at the
discretion of the Investigator

- Use of GLP-1, GLP-2, human growth hormone (HGH), dipeptidyl peptidase-4 (DPP-4)
inhibitors, somatostatin, or analogs thereof within 3 months. Note: Prior use of
glepaglutide trial drug is allowed

- Females of childbearing potential, who are pregnant, breast-feeding, intend to become
pregnant, or are not using highly effective contraceptive methods

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/9/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Ryan Hurt, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Karen Evans

(507) 422-2944

Evans.Karen@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20556003

Mayo Clinic Footer